Literature DB >> 23114512

Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial.

Heather A Pines1, Pamina M Gorbach, Robert E Weiss, Kristen Hess, Ryan Murphy, Terry Saunders, Joelle Brown, Peter A Anton, Ross D Cranston.   

Abstract

We assessed the acceptability of three of over-the-counter products representative of potential rectal microbicide (RM) delivery systems. From 2009 to 2010, 117 HIV-uninfected males (79 %) and females (21 %) who engage in receptive anal intercourse participated in a 6-week randomized crossover acceptability trial. Participants received each of three products (enema, lubricant-filled applicator, suppository) every 2 weeks in a randomized sequence. CASI and T-ACASI scales assessed product acceptability via Likert responses. Factor analysis was used to identify underlying factors measured by each scale. Random effects models were fit to examine age and gender effects on product acceptability. Three underlying factors were identified: Satisfaction with Product Use, Sexual Pleasure, and Ease of Product Use. For acceptability, the applicator ranked highest; however, differences between product acceptability scores were greatest among females and younger participants. These findings indicate that RM delivery systems impact their acceptability and should be considered early in RM development to enhance potential use.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23114512      PMCID: PMC3594349          DOI: 10.1007/s10461-012-0358-z

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  20 in total

1.  Frequent use of lubricants for anal sex among men who have sex with men: the HIV prevention potential of a microbicidal gel.

Authors:  A Carballo-Diéguez; Z Stein; H Sáez; C Dolezal; L Nieves-Rosa; F Díaz
Journal:  Am J Public Health       Date:  2000-07       Impact factor: 9.308

Review 2.  Vaginal douching: evidence for risks or benefits to women's health.

Authors:  Jenny L Martino; Sten H Vermund
Journal:  Epidemiol Rev       Date:  2002       Impact factor: 6.222

3.  Sexual behaviors and situational characteristics of most recent male-partnered sexual event among gay and bisexually identified men in the United States.

Authors:  Joshua G Rosenberger; Michael Reece; Vanessa Schick; Debby Herbenick; David S Novak; Barbara Van Der Pol; J Dennis Fortenberry
Journal:  J Sex Med       Date:  2011-08-24       Impact factor: 3.802

4.  Per-contact risk of human immunodeficiency virus transmission between male sexual partners.

Authors:  E Vittinghoff; J Douglas; F Judson; D McKirnan; K MacQueen; S P Buchbinder
Journal:  Am J Epidemiol       Date:  1999-08-01       Impact factor: 4.897

5.  Effects of partnership change on microbicide gel adherence in a clinical trial (HPTN 035).

Authors:  Pamina M Gorbach; Clifton W Kelly; Joleen A Borgerding; Gita Ramjee; Tchangani Tembo; Newton Kumwenda; Petina Musara; Sarah Roberts; Lisa Maslankowski
Journal:  AIDS Behav       Date:  2014-05

6.  Preference and practices relating to lubricant use during anal intercourse: implications for rectal microbicides.

Authors:  Marjan Javanbakht; Ryan Murphy; Pamina Gorbach; Marc-André LeBlanc; Jim Pickett
Journal:  Sex Health       Date:  2010-06       Impact factor: 2.706

7.  Rectal microbicide acceptability: results of a volume escalation trial.

Authors:  Alex Carballo-Diéguez; Theresa Exner; Curtis Dolezal; Robert Pickard; Peter Lin; Kenneth H Mayer
Journal:  Sex Transm Dis       Date:  2007-04       Impact factor: 2.830

8.  Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use.

Authors:  Beens Varghese; Julie E Maher; Thomas A Peterman; Bernard M Branson; Richard W Steketee
Journal:  Sex Transm Dis       Date:  2002-01       Impact factor: 2.830

9.  Rectal microbicides for U.S. gay men. Are clinical trials needed? Are they feasible? HIVNET Vaccine Preparedness Study Protocol Team.

Authors:  M Gross; S P Buchbinder; C Celum; P Heagerty; G R Seage
Journal:  Sex Transm Dis       Date:  1998-07       Impact factor: 2.830

10.  Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men.

Authors:  Ana Ventuneac; Alex Carballo-Diéguez; Ian McGowan; Robert Dennis; Amy Adler; Elena Khanukhova; Charles Price; Terry Saunders; Chomchay Siboliban; Peter Anton
Journal:  AIDS Behav       Date:  2009-09-11
View more
  16 in total

1.  Rectal-specific microbicide applicator: evaluation and comparison with a vaginal applicator used rectally.

Authors:  Alex Carballo-Diéguez; Rebecca Giguere; Curtis Dolezal; José Bauermeister; Cheng-Shiun Leu; Juan Valladares; Lisa C Rohan; Peter A Anton; Ross D Cranston; Irma Febo; Kenneth Mayer; Ian McGowan
Journal:  AIDS Behav       Date:  2014-09

2.  Commercial lubricant use among HIV-negative men who have sex with men in Los Angeles: implications for the development of rectal microbicides for HIV prevention.

Authors:  Heather A Pines; Pamina M Gorbach; Cathy J Reback; Raphael J Landovitz; Matt G Mutchler; Ronald Mitsuyasu
Journal:  AIDS Care       Date:  2014-07-15

3.  Preparing for rectal microbicides: sociocultural factors affecting product uptake among potential South American users.

Authors:  Jerome T Galea; Janni J Kinsler; John Imrie; César R Nureña; Lucía Ruiz; Luis Fernando Galarza; Jorge Sánchez; William E Cunningham
Journal:  Am J Public Health       Date:  2014-04-17       Impact factor: 9.308

4.  Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis.

Authors:  Corrine Ying Xuan Chua; Priya Jain; Andrea Ballerini; Giacomo Bruno; R Lyle Hood; Manas Gupte; Song Gao; Nicola Di Trani; Antonia Susnjar; Kathryn Shelton; Lane R Bushman; Marco Folci; Carly S Filgueira; Mark A Marzinke; Peter L Anderson; Ming Hu; Pramod Nehete; Roberto C Arduino; Jagannadha K Sastry; Alessandro Grattoni
Journal:  J Control Release       Date:  2018-08-06       Impact factor: 9.776

Review 5.  Designing and developing suppository formulations for anti-HIV drug delivery.

Authors:  Anthony S Ham; Robert W Buckheit
Journal:  Ther Deliv       Date:  2017-08

Review 6.  On-demand microbicide products: design matters.

Authors:  Sravan Kumar Patel; Lisa Cencia Rohan
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

7.  Patterns of a Rectal Microbicide Placebo Gel Use in a Preparatory Stage for a Phase I Trial Among Young Men Who Have Sex with Men.

Authors:  José A Bauermeister; R Giguere; C S Leu; C Dolezal; I Febo; R D Cranston; K Mayer; I McGowan; A Carballo-Diéguez
Journal:  AIDS Behav       Date:  2018-02

8.  Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.

Authors:  Alex Carballo-Diéguez; Rebecca Giguere; Curtis Dolezal; Cheng-Shiun Leu; Iván C Balán; William Brown; Christine Rael; Barbra A Richardson; Jeanna M Piper; Linda-Gail Bekker; Suwat Chariyalertsak; Anupong Chitwarakorn; Pedro Gonzales; Timothy H Holtz; Albert Liu; Kenneth H Mayer; Carmen D Zorrilla; Javier R Lama; Ian McGowan; Ross D Cranston
Journal:  AIDS Behav       Date:  2017-12

9.  Lessons for Rectal Microbicide Development From an Acceptability Trial of a Placebo Gel Applied Prior to Receptive Anal Intercourse.

Authors:  Timothy Frasca; Rebecca Giguere; Mobolaji Ibitoye; Curtis Dolezal; Irma Febo; Ross D Cranston; Kenneth Mayer; Ian McGowan; Alex Carballo-Diéguez
Journal:  Arch Sex Behav       Date:  2016-04-29

10.  Rectal douching and implications for rectal microbicides among populations vulnerable to HIV in South America: a qualitative study.

Authors:  Jerome T Galea; Janni J Kinsler; John Imrie; César R Nureña; Jorge Sánchez; William E Cunningham
Journal:  Sex Transm Infect       Date:  2013-08-21       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.